BMS Opdivo To Make Splash in Blood Cancer
New data show that Bristol-Myers Squibb Co.'s Opdivo (nivolumab) has promise in treating Hodgkin's lymphoma reinforcing the notion that checkpoint inhibitors have potential in a broad range of cancers.
You may also be interested in...
Seattle Genetics/BMS Blood Cancer Tie-Up May Expand After Good Combo Data
Combo of Seattle Genetics' antibody-drug conjugate Adcetris and BMS's PD-1 inhibitor Opdivo demonstrates 90% objective response rate and 62% complete response rate in relapsed Hodgkin lymphoma, and further investigation of the pairing seems on the cards.
Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Merck claims to have the broadest clinical development program for an anti-PD-1/L1 drug, with more than 270 trials under way testing Keytruda in 30 tumor types and 100 combinations.
Merck's Keytruda Gets Lung Cancer Nod In Europe
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an expanded indication for Merck & Co.’s PD-1 antagonist Keytruda (pembrolizumab).